FDA OTP panel urges early engagement, clear packaging and disciplined meeting prep for BLA submissions for cell and gene therapies

The U.S. Food and Drug Administration's Office of Therapeutic Products (OTP) hosted a virtual town hall to walk sponsors through best practices for preparing Biologics License Applications (BLAs) for cell and gene therapy products, emphasizing early engagement, clear submission packaging and disciplined meeting preparation. OTP leaders said these steps reduce the risk of filing delays or technical rejections.

"Most important thing you do before you submit, request meeting with CBER," said Nadia Whitt, chief of Branch 1, urging sponsors to use pre-BLA meetings to clarify expectations. Whitt warned that incomplete manufacturing process descriptions, inadequately justified specifications, missing GLP nonclinical reports or incomplete Module 1 paperwork are common sources of delay.

The panel recommended a predictable timeline for pre-meeting planning: Jessica Boehmer, ORMRR associate director for regulatory policy, advised sponsors to request a pre-BLA meeting "no later than four months prior to the anticipated BLA submission date," noting that OTP generally schedules a granted pre-BLA meeting within about 60 days of receipt and typically grants one pre-BLA meeting per product and indication.

Tyree Newman, chief of Branch 3, said pre-BLA meetings are not required but are "highly recommended" and advised teams to prioritize questions during the meeting, limit introductory presentations to a few minutes, and reserve five to ten minutes at the end to summarize action items and ensure mutual understanding.

OTP staff outlined technical and procedural precautions for assembling the submission. To avoid eCTD technical rejection, Newman emphasized including the U.S. regional XML file, using the correct folder and file structure, matching application type and numbers to the corresponding FDA forms, and submitting a complete FDA Form 356h; an incomplete or missing 356h will trigger automatic rejection.

On master files and manufacturing content, Whitt cited the FDA's October 2019 draft guidance on drug master files and said that, at the BLA stage, the agency generally expects manufacturing information to be submitted directly in the BLA rather than incorporated solely by reference to a master file.

The panel also reviewed milestones in the review cycle: Newman described the 60-day filing review to determine if an application will be accepted for substantive review, the multidisciplinary team assignment, and the routine issuance of information requests (IRs) from any discipline. Jessica Boehmer summarized PDUFA-era mid-cycle and late-cycle meetings: mid-cycle communications (typically around five to six months after filing for standard reviews and two to three months for priority reviews) are checkpoints to flag major issues; late-cycle meetings (scheduled no later than about three months before the PDUFA goal date for standard reviews) address unresolved clinical, labeling or manufacturing concerns and anticipated postmarketing requirements.

On rolling review, Boehmer said the pathway is limited to applications with RMAT, breakthrough therapy or fast-track designation and should be discussed at the pre-BLA meeting. Nadia Whitt clarified: "The rolling review is not considered received until the final module is submitted," and the review clock begins when the final module is in.

Panelists advised sponsors developing an integral companion device to engage early with both CBER/OTP and the Center for Devices and Radiological Health (CDRH) and, if uncertain about jurisdiction, to contact the Office of Combination Products to request designation. OTP staff said the agency coordinates cross-center review and works to align device and biologic timelines when needed.

When asked about the agency's use of artificial intelligence in expedited workstreams, Jessica Boehmer said teams used AI tools to summarize large volumes of data and sharpen presentations during a compressed review process, but that "AI is a tool for reviewers, not replacement for judgment in the review." She emphasized that scientific decisions and review judgments were made by human reviewers.

OTP closed by pointing sponsors to filing checklists and SOPP references (including SOPP 8401 and SOPP 8404 for filing and refuse-to-file processes and SOPP 8413 for postmarketing commitments), encouraging use of a reviewer's guide in Section 1.2 to orient reviewers, and reminding attendees that recordings and transcripts will be posted on FDA.gov and the agency's YouTube channel.

The town hall concluded with contact information for project managers (OTPRPMS@FDA.HHS.GOV) and a reminder that OTP cannot address questions about specific products or unpublished guidance during the session. The recording and transcript will be posted on FDA.gov.